Formycon AG (FYB.DE)

Executive Summary

Formycon AG is a German biopharmaceutical company focused on developing high-quality biosimilars and long-acting biologics. With a pipeline including approved products FYB201 and FYB203 (biosimilars to Lucentis and Eylea, respectively) for ophthalmology, and FYB206 (biosimilar to Keytruda) in Phase 1/3 for oncology, Formycon leverages partnerships for commercialization. The company's proprietary platform for extended-action biologics offers additional differentiation. Financially, Formycon is publicly traded on the Frankfurt Stock Exchange with a market cap of ~€320M. Near-term revenue growth is expected from FYB201/FYB203 launches in Europe, while FYB206 represents a major pipeline value driver pending clinical data. However, the termination of a Phase 3 trial for FYB206 in non-small cell lung cancer highlights development risks. Overall, Formycon is positioned to capture share in the growing biosimilar market, but execution and competitive dynamics remain key.

Upcoming Catalysts (preview)

• Q3 2026European Commission approval for FYB203 (aflibercept biosimilar)80% success
• H2 2026Phase 1 data readout for FYB206 (pembrolizumab biosimilar) in melanoma70% success
• Q4 2026Potential partnership or licensing deal for FYB206 or other pipeline assets50% success